Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence
Authors' conclusion
Fenofibrate use was associated with a reduced risk of STDR in individuals with T2D in the real-world clinical practice.
Study context
- Population
- Adults (≥18 years) with T2D receiving statins or fenofibrate, Clinical Practice Research Datalink (UK primary care database), 1 January 2000 to 30 June 2022propensity score-matched
- Participants
- 16,337 vs 25,764
- Comparison
- Fenofibrate vs statins
- Fenofibraten = 16,337
- Statinn = 25,764reference
- Outcome
- Incident sight-threatening diabetic retinopathy (STDR)
- Follow-up
- Up to 12 years
Methodological detailspropensity score-matched, prevalent new-user design, competing risk Cox proportional hazard regression
- Propensity score-matched
- Prevalent new-user design
- Competing risk Cox proportional hazard regression
Main finding
As reported in the abstract
Incident STDR
Fenofibrate vs StatinAdjusted hazard ratio (95% CI)
ITT analysis
0.87(0.82–0.93)
Per-protocol analysis
0.80(0.74–0.87)
Further findings
Sight-threatening diabetic retinopathy (STDR) in sensitivity analyses and subgroups (age, sex, ethnicity, lipid levels)
- Results consistent across sensitivity analysis and subgroups based on age, sex, ethnicity and lipid levels
- Protective effect not observed in South Asians
Original publication
Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence. J Clin Endocrinol Metab. Published 7 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →